Legislation introduced to create a new drug safety office at the FDA

BMJ 2005; 330 doi: http://dx.doi.org/10.1136/bmj.330.7499.1044-f (Published 5 May 2005)
Cite this as: BMJ 2005;330:1044.7

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jeanne Lenzer
  1. New York

    After a year of controversy at the US Food and Drug Administration over drug safety, Senators Chuck Grassley (Republican, Iowa) and Chris Dodd (Democrat, Connecticut), introduced legislation last week to establish an independent office of drug safety at the agency.

    The Food and Drug Administration Safety Act of 2005, if passed, will establish a Center for Post-market Drug Evaluation and Research. Its director would report directly to the FDA commissioner. Currently, the FDA's Office of Drug Safety serves in a consultative role to the Office of New Drugs.

    David Graham, the FDA scientist who …

    Get access to this article and all of bmj.com for the next 14 days

    Sign up for a 14 day free trial today

    Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL